403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
ARC Medical Announces Upcoming Meeting Schedule
(MENAFN- EIN Presswire) EINPresswire/ -- ARC Medical Inc. ("ARC"), a leader in surgical adhesion prevention innovation, plans to participate in the following events during the first half of 2026:
●BIO Investment & Growth Summit: March 2–3, Miami, FL
●Canaccord Genuity Musculoskeletal Conference: March 2–3, New Orleans, LA
●AAOS (American Academy of Orthopedic Surgeons): March 2–6, New Orleans, LA
●AdvaMed CEO Summit: March 9–10, Scottsdale, AZ
●LSX Investival Showcase USA: March 10–11, Miami, FL
●LSI USA Emerging Medtech Summit: March 16–20, Dana Point, CA
●Bloom Burton & Co. Healthcare Investor Conference: April 21–22, Toronto, ON
●BIO International Convention: June 22–25, Boston, MA
ARC Management will be meeting with investors, potential strategic partners, key opinion leader surgeons and investment banks during these events in anticipation of near term, key milestones.
ARC's liquid adhesion barrier medical devices, JOCOATTM and IPCOATTM, are undergoing confirmatory pivotal clinical trials to support regulatory approvals outside the United States and serve as pilot clinical trials for the United States. Topline data readouts are anticipated for the Company's JOCOATTM orthopedic clinical trial as soon as Q3 2026 and ARC's IPCOATTM gynecologic clinical trial as early as Q1 2027.
Dr. Chris Springate, Chief Executive Officer of ARC, stated,“Our focus in H1 2026 is disciplined execution across our clinical, regulatory and commercial strategic priorities. As our pivotal clinical trials advance, we are preparing for regulatory approval submissions while engaging with key stakeholders to ensure alignment ahead of commercialization of JOCOATTM and IPCOATTM. These meetings provide an opportunity to highlight our progress, outline our regulatory and reimbursement pathways, and continue to build the relationships necessary to support the next phase of ARC's commercialization.”
About JOCOATTM
JOCOATTM liquid surgical adhesion barrier device is easily and rapidly applied into the joint at the end of an orthopedic surgery in arthroscopy and open procedures. JOCOATTM then flows and provides a temporary, physical barrier that mechanically separates the tissues and prevents or reduces surgical adhesions throughout the entire joint. The objectives of the current JOCOATTM GLAD-04 knee anterior cruciate ligament (ACL) repair surgery clinical trial include assessing the efficacy, safety, usability and manageability of JOCOAT.
About IPCOATTM
IPCOATTM liquid adhesion barrier device is easily and rapidly applied into the peritoneal cavity at the end of a gynecologic, obstetric or abdominal surgery in laparoscopic and open procedures. IPCOATTM then flows and provides a temporary, physical barrier that mechanically separates the tissues and prevents or reduces adhesions throughout the entire abdominopelvic cavity. The objectives of the approaching IPCOATTM GLAD-02 gynecologic endometriosis surgery patient clinical trial include assessing the efficacy, safety, usability and manageability of IPCOATTM.
Why the Prevention of Surgical Adhesions Matters
Surgical adhesions are internal bands of scar tissue that form between organs and tissues after surgery, causing them to stick together. They are the most common postoperative complication, contributing to immobility, chronic pelvic pain, infertility, bowel obstruction, and challenging reoperations to cut apart adhesions after they form. Despite advances in minimally invasive surgery techniques, surgical adhesion formation remains a significant risk of common surgeries.
About ARC Medical Inc.
ARC Medical is a clinical stage, privately held medical device company commercializing next generation, liquid adhesion barrier medical devices to prevent surgical adhesions.
Caution: JOCOATTM and IPCOATTM are investigational devices and are limited by law in the United States and other countries to investigational use.
Investor and Partner Contact
Chris Springate, CEO
ARC Medical Inc.
Email:...
LinkedIn:
Media Contact
●BIO Investment & Growth Summit: March 2–3, Miami, FL
●Canaccord Genuity Musculoskeletal Conference: March 2–3, New Orleans, LA
●AAOS (American Academy of Orthopedic Surgeons): March 2–6, New Orleans, LA
●AdvaMed CEO Summit: March 9–10, Scottsdale, AZ
●LSX Investival Showcase USA: March 10–11, Miami, FL
●LSI USA Emerging Medtech Summit: March 16–20, Dana Point, CA
●Bloom Burton & Co. Healthcare Investor Conference: April 21–22, Toronto, ON
●BIO International Convention: June 22–25, Boston, MA
ARC Management will be meeting with investors, potential strategic partners, key opinion leader surgeons and investment banks during these events in anticipation of near term, key milestones.
ARC's liquid adhesion barrier medical devices, JOCOATTM and IPCOATTM, are undergoing confirmatory pivotal clinical trials to support regulatory approvals outside the United States and serve as pilot clinical trials for the United States. Topline data readouts are anticipated for the Company's JOCOATTM orthopedic clinical trial as soon as Q3 2026 and ARC's IPCOATTM gynecologic clinical trial as early as Q1 2027.
Dr. Chris Springate, Chief Executive Officer of ARC, stated,“Our focus in H1 2026 is disciplined execution across our clinical, regulatory and commercial strategic priorities. As our pivotal clinical trials advance, we are preparing for regulatory approval submissions while engaging with key stakeholders to ensure alignment ahead of commercialization of JOCOATTM and IPCOATTM. These meetings provide an opportunity to highlight our progress, outline our regulatory and reimbursement pathways, and continue to build the relationships necessary to support the next phase of ARC's commercialization.”
About JOCOATTM
JOCOATTM liquid surgical adhesion barrier device is easily and rapidly applied into the joint at the end of an orthopedic surgery in arthroscopy and open procedures. JOCOATTM then flows and provides a temporary, physical barrier that mechanically separates the tissues and prevents or reduces surgical adhesions throughout the entire joint. The objectives of the current JOCOATTM GLAD-04 knee anterior cruciate ligament (ACL) repair surgery clinical trial include assessing the efficacy, safety, usability and manageability of JOCOAT.
About IPCOATTM
IPCOATTM liquid adhesion barrier device is easily and rapidly applied into the peritoneal cavity at the end of a gynecologic, obstetric or abdominal surgery in laparoscopic and open procedures. IPCOATTM then flows and provides a temporary, physical barrier that mechanically separates the tissues and prevents or reduces adhesions throughout the entire abdominopelvic cavity. The objectives of the approaching IPCOATTM GLAD-02 gynecologic endometriosis surgery patient clinical trial include assessing the efficacy, safety, usability and manageability of IPCOATTM.
Why the Prevention of Surgical Adhesions Matters
Surgical adhesions are internal bands of scar tissue that form between organs and tissues after surgery, causing them to stick together. They are the most common postoperative complication, contributing to immobility, chronic pelvic pain, infertility, bowel obstruction, and challenging reoperations to cut apart adhesions after they form. Despite advances in minimally invasive surgery techniques, surgical adhesion formation remains a significant risk of common surgeries.
About ARC Medical Inc.
ARC Medical is a clinical stage, privately held medical device company commercializing next generation, liquid adhesion barrier medical devices to prevent surgical adhesions.
Caution: JOCOATTM and IPCOATTM are investigational devices and are limited by law in the United States and other countries to investigational use.
Investor and Partner Contact
Chris Springate, CEO
ARC Medical Inc.
Email:...
LinkedIn:
Media Contact
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment